trimethoprim has been researched along with epiroprim in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 16 (59.26) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Richards, WG; So, SS | 1 |
| Hansch, C; Li, RL; Poe, M; Selassie, CD | 1 |
| Debnath, G; Fang, ZX; Hansch, C; Kaufman, BT; Klein, TE; Langridge, R; Li, RL; Selassie, CD | 1 |
| Fang, ZX; Hansch, C; Kaufman, BT; Klein, T; Langridge, R; Li, RL; Selassie, CD | 1 |
| Queener, SF | 1 |
| Marlowe, CK; Santi, DV; Selassie, CD | 1 |
| Gangjee, A; Kisliuk, RL; Queener, SF; Vasudevan, A | 1 |
| Gangjee, A; Queener, SF; Vasudevan, A | 1 |
| Papoulis, AT; Queener, SF; Rosowsky, A | 1 |
| Cody, V; Galitsky, N; Gangjee, A; Guo, X; Luft, JR; Pangborn, W; Queener, SF | 1 |
| Loukas, YL | 1 |
| Forsch, RA; Queener, SF; Rosowsky, A | 1 |
| Chan, DC; Fu, H; Queener, SF; Rosowsky, A | 1 |
| Boesche, M; Crowther, GJ; Dasari, KS; Drewes, G; El Bakkouri, M; Fox, AM; Ghidelli-Disse, S; He, P; Hillesland, HK; Hui, R; Jones, JC; Keyloun, KR; Krahn, MM; Lafuente-Monasterio, MJ; Leonard, SE; Leroy, D; Maly, DJ; Mo, JS; Ojo, KK; Reid, MC; Rivas, KL; Van Voorhis, WC | 1 |
| Bera, S; Mondal, D | 1 |
| Dankert, W; Hartman, PG; Mehlhorn, H; Then, RL | 1 |
| Arsenijevic, D; Chang, HR; Comte, R; Pechère, JC; Polak, A; Then, RL | 1 |
| Foy, J; Steele, P; Walzer, PD; White, M | 1 |
| Allegra, CJ; Kovacs, JA; Martinez, A | 1 |
| Angehrn, P; Hartman, PG; Locher, HH; Schlunegger, H; Then, RL | 1 |
| Brun-Pascaud, M; Chau, F; Derouin, F; Garry, L; Girard, PM; Jacobus, D | 1 |
| Chang, HR; Khoo, YM; Lee, HS | 1 |
| Dhople, AM | 3 |
| Chavarot, P; Dosso, M; Marchal, G; N'guessan, K; Pescher, P; Romain, F | 1 |
| Guentert, TW; Lavé, T; Luttringer, O; Poulin, P; Schmitt-Hoffmann, AH; Theil, FP | 1 |
2 review(s) available for trimethoprim and epiroprim
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
25 other study(ies) available for trimethoprim and epiroprim
| Article | Year |
|---|---|
Application of neural networks: quantitative structure-activity relationships of the derivatives of 2,4-diamino-5-(substituted-benzyl)pyrimidines as DHFR inhibitors.
Topics: Drug Design; Folic Acid Antagonists; Neural Networks, Computer; Pyrimidines; Regression Analysis; Structure-Activity Relationship | 1992 |
On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.
Topics: Diamines; Escherichia coli; Folic Acid Antagonists; Kinetics; Lacticaseibacillus casei; Molecular Structure; Protein Binding; Pyrimidines; Structure-Activity Relationship | 1991 |
On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships.
Topics: Animals; Chemical Phenomena; Chemistry; Chickens; Drug Design; Folic Acid Antagonists; Lacticaseibacillus casei; Liver; Pyrimidines; Structure-Activity Relationship; X-Ray Diffraction | 1989 |
Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A quantitative structure-activity relationship and graphics analysis.
Topics: Animals; Chickens; Crystallography; Enzyme Inhibitors; Folic Acid Antagonists; Liver; Mathematics; Models, Molecular; Pyrimidines; Structure-Activity Relationship; Trimethoprim; X-Ray Diffraction | 1986 |
Quantitative structure-activity relationships of the inhibition of Pneumocystis carinii dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(X-phenyl)-s-triazines.
Topics: Folic Acid Antagonists; Fungal Proteins; Kinetics; Pneumocystis; Structure-Activity Relationship; Triazines | 1995 |
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Liver; Mice; Molecular Structure; Neoplasms, Experimental; Pneumocystis; Pyrimidines; Rats; Recombinant Proteins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1996 |
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
Topics: AIDS-Related Opportunistic Infections; Animals; Folic Acid Antagonists; Humans; Liver; Mice; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimetrexate | 1997 |
2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Topics: Animals; Enzyme Inhibitors; Folic Acid Antagonists; Liver; Magnetic Resonance Spectroscopy; Pneumocystis; Pyrimidines; Rats; Tetrahydrofolate Dehydrogenase; Thiophenes; Toxoplasma | 1997 |
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Drug Design; Folic Acid Antagonists; Liver; Models, Molecular; NAD; Naphthalenes; Phenylalanine; Pneumocystis; Pyrimidines; Rats; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma | 1998 |
Adaptive neuro-fuzzy inference system: an instant and architecture-free predictor for improved QSAR studies.
Topics: Algorithms; Folic Acid Antagonists; Multivariate Analysis; Pyrimidines; Quantitative Structure-Activity Relationship; Regression Analysis; Tetrahydrofolate Dehydrogenase | 2001 |
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
Topics: Animals; Folic Acid Antagonists; Liver; Mycobacterium avium; Pneumocystis; Pyrimidines; Rats; Species Specificity; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Trimethoprim | 2002 |
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
Topics: Animals; Azepines; Benzazepines; Folic Acid Antagonists; Models, Molecular; Mycobacterium avium; Pneumocystis carinii; Pteridines; Rats; Solubility; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Toxoplasma; Water | 2004 |
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
Topics: Antimalarials; Calcium; Cell Line, Tumor; Hep G2 Cells; Humans; Malaria, Falciparum; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Plasmodium falciparum; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protozoan Proteins | 2016 |
A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Dapsone; Drug Therapy, Combination; Female; Folic Acid Antagonists; Male; Mice; Mice, Inbred Strains; Mice, Nude; Mice, SCID; Pilot Projects; Pneumocystis; Pneumocystis Infections; Pyrimethamine; Rats; Rats, Nude; Sodium Chloride; Sulfadiazine; Toxoplasma; Toxoplasmosis, Animal; Trimethoprim | 1995 |
Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
Topics: Animals; Dapsone; Drug Synergism; Female; Folic Acid Antagonists; Mice; Toxoplasma; Toxoplasmosis, Animal; Trimethoprim; Uracil | 1994 |
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Dapsone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Folic Acid Antagonists; Immunosuppression Therapy; Male; Pneumonia, Pneumocystis; Rats; Rats, Sprague-Dawley; Sulfamethoxazole; Trimethoprim | 1993 |
Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Topics: Acute Disease; Administration, Oral; Animals; Anti-Infective Agents; Antiprotozoal Agents; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; Half-Life; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Sulfadiazine; Toxoplasmosis, Animal; Trimethoprim | 1996 |
Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.
Topics: Animals; Dapsone; Drug Combinations; Folic Acid Antagonists; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mice; Microbial Sensitivity Tests; Sepsis; Trimethoprim | 1996 |
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; Immunosuppression Therapy; Pneumocystis Infections; Proguanil; Pyrimethamine; Rats; Rats, Wistar; Tetrahydrofolate Dehydrogenase; Toxoplasma; Toxoplasmosis, Animal; Trimethoprim | 1996 |
Simple HPLC determination of the concentrations of epiroprim in the serum and brains of mice.
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Folic Acid Antagonists; Mice; Trimethoprim | 1996 |
In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
Topics: Cell-Free System; Dapsone; Folic Acid Antagonists; Leprostatic Agents; Microbial Sensitivity Tests; Mycobacterium leprae; Trimethoprim | 1999 |
Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans.
Topics: Anti-Bacterial Agents; Dapsone; Drug Therapy, Combination; Folic Acid Antagonists; Humans; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Tetrahydrofolate Dehydrogenase; Trimethoprim | 2001 |
In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae.
Topics: Administration, Oral; Animals; Armadillos; Dapsone; Drug Synergism; Female; Folic Acid Antagonists; Leprostatic Agents; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Trimethoprim | 2002 |
[Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model].
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Trimethoprim; Tuberculosis, Pulmonary | 2002 |
Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.
Topics: Animals; Body Weight; Cells, Cultured; Chromatography, High Pressure Liquid; Dogs; Hepatocytes; Humans; Macaca; Male; Mice; Models, Biological; Species Specificity; Time Factors; Tissue Distribution; Trimethoprim | 2003 |